Eghierhua Ugheoke, MD
Gastroenterology · Huntsville, ALNPI 1588603955
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,816 of the $10,177 with a category attached, or 86.6%. 36 manufacturers reported payments, led by AbbVie at 31.6% of the total.
Across 591 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Medtronic$1K
- Johnson & Johnson$562
- Braintree Laboratories, Inc.$284
- Gilead$271
- plus $2K from 30 others
What the payments were for
- Travel & lodging$1,04810%
- Food & beverage$8,81687%
- Education$450%
- Gifts$2683%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 179 | $3,216 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 237 | $2,220 |
| Medtronic | 15 | $1,243 |
| Johnson & Johnson | 35 | $562 |
| Braintree Laboratories, Inc. | 5 | $284 |
| Gilead | 12 | $271 |
| Redhill Biopharma Inc. | 12 | $240 |
| Madrigal Pharmaceuticals | 9 | $234 |
| Merck | 10 | $209 |
| Ferring Pharmaceuticals Inc. | 9 | $201 |
| Phathom Pharmaceuticals, Inc. | 13 | $187 |
| Evoke Pharma, Inc. | 10 | $176 |
| Fujifilm Healthcare Americas Corporation | 1 | $151 |
| Celltrion USA Inc. | 6 | $131 |
| Ardelyx, Inc. | 6 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $113 |
| Apollo Endosurgery US Inc | 1 | $103 |
| Ironwood Pharmaceuticals, Inc | 6 | $90 |
| Lilly USA, LLC | 2 | $44 |
| Covidien LP | 1 | $30 |
| Pentax Of America, Inc. | 1 | $30 |
| Sandoz | 1 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Pfizer | 1 | $29 |
| Sanofi | 1 | $26 |
| Boehringer Ingelheim | 1 | $24 |
| QOL Medical, LLC | 1 | $23 |
| Intercept Pharmaceuticals, Inc. | 1 | $22 |
| Enterra Medical, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Fresenius Kabi USA, LLC | 1 | $17 |
| Bristol Myers Squibb | 1 | $15 |
| Intra-sana Laboratories | 1 | $14 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GI Genius$934
- Skyrizi$230
- X-Tack Endoscopic HeliX Tacking System$206
- FUJIFILM$151
- Tremfya$131
- Rinvoq$110
- OverStitch Endoscopic Suturing System$103
How this compares
$10,177 in reported general payments places this provider in the 80th percentile of 225 gastroenterology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntyvioVedolizumab | 13 | $107,827 |
| XifaxanRifaximin | 19 | $61,392 |
| Octreotide Acetate | 13 | $13,690 |
| LinzessLinaclotide | 16 | $13,579 |
| Budesonide DrBudesonide | 33 | $7,177 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 46 | $6,370 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 23 | $3,904 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 42 | $2,645 |
| Mesalamine ErMesalamine | 16 | $2,562 |
| Azathioprine | 13 | $2,531 |
| Dicyclomine Hcl | 54 | $2,092 |
| Omeprazole | 174 | $2,090 |
| Pantoprazole Sodium | 122 | $1,578 |
| Sucralfate | 22 | $1,325 |
| Budesonide EcBudesonide | 11 | $1,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $113 | $107,82713 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $2,220 | $67,76365 claims |
| AbbVieLinzess | $3,216 | $13,57916 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $201 | $3,90423 claims |
| SandozLansoprazole | $29 | $90511 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $17 | $3715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 225 gastroenterology providers in Alabama.
Other gastroenterology in Huntsville
- John-Paul VoelkelHuntsville$17K
- Meredith RoathHuntsville$16K
- Charles BillingsHuntsville$16K
- Dino FerranteHuntsville$15K
- Suresh KarneHuntsville$12K
- Rami HawariHuntsville$10K
- Prasad VankineniHuntsville$10K
- Jason KinzelHuntsville$10K
- Keta VaidyaHuntsville$9K
- Michael DohrenwendHuntsville$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.